Yashima F, Hara M, Inohara T, et al. - Researchers undertook this observational analysis to assess how statin therapy can influence midterm mortality of transcatheter aortic valve implantation (TAVI) patients. They used a Japanese multicentre registry to find out patients with aortic stenosis who received TAVI. A total of 2588 patients (84.4±5.2 years) were included, most of them were females (69.3%). Depending on statin at admission, patients were classified, and 936 matched pairs were found post-propensity score matching. A significant decrease in all-cause mortality and cardiovascular mortality was evident in relation to statin at admission. A significantly lower all-cause mortality was observed in the octogenarians in relation to statin therapy; but nonagenarians seemed to experience a lower impact. A significant difference in all-cause mortality was observed on comparing four groups based on previous coronary artery disease (CAD) and statin, and the worst prognosis was seen in patients who did not receive statin despite previous CAD. Overall, statin therapy will confer benefits even in octogenarians TAVI patients, however, the benefits may disappear in nonagenarians. Additionally, statin will remain essential for TAVI patients with CAD.